Jinarc: first treatment for polycystic kidney disease

Jinarc (tolvaptan) is the first drug to target the underlying pathophysiology of autosomal dominant polycystic kidney disease (ADPKD).

ADPKD is a genetic disorder characterised by the growth of fluid-filled cysts in the kidney that reduce kidney function and ultimately lead to kidney failure. | SCIENCE PHOTO LIBRARY
ADPKD is a genetic disorder characterised by the growth of fluid-filled cysts in the kidney that reduce kidney function and ultimately lead to kidney failure. | SCIENCE PHOTO LIBRARY

ADPKD is a chronic and progressive genetic disease that causes the proliferation and growth of cysts in the kidneys. Existing drugs only treat the signs and symptoms of ADPKD (kidney cysts, pain and hypertension).

Tolvaptan is a selective vasopressin V2-receptor antagonist that slows cyst growth and renal function decline. It is administered in a twice-daily split-dose regimen, with the morning dose taken at least 30 minutes before food.

Clinical Studies

Further information
View Jinarc drug record
Summary of Product Characteristics
Manufacturer: Otsuka

Safety and efficacy of tolvaptan were assessed in a multicentre, double-blind, phase III trial (n=1445). Patients with evidence of rapidly progressing early ADPKD (total kidney volume ≥750ml, estimated CrCl ≥60ml/min) were randomised to receive placebo or the highest tolerable of three twice-daily regimens of tolvaptan.

Over the 3-year study period, the rate of total kidney volume increase in the tolvaptan group was 2.8% per year (95% CI 2.5—3.1) compared with 5.5% per year in the placebo group (95% CI 5.1—6.0; p<0.001). Tolvaptan was associated with a significant reduction in the risk of multiple events of worsening renal function, pain, hypertension or albuminuria (HR 0.87, 95% CI 0.78—0.97; p=0.0095).

Safety profile

The most commonly reported adverse effects of tolvaptan were thirst, polyuria, nocturia and pollakiuria.

Clinically significant liver enzyme elevations were more common with tolvaptan than placebo (4.9% vs 1.2%). No cases of hepatic failure were reported; however, additional monitoring is recommended to mitigate the potential risk of irreversible liver injury. Prescribers should monitor patients' liver function before starting treatment with tolvaptan, and monthly for the first 18 months and every three months thereafter.

The safety and efficacy of tolvaptan in CKD stage 5 has not been adequately studied; therefore treatment should be discontinued if renal insufficiency progresses to CKD stage 5.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases